T6247

Onvansertib (NMS-1286937) is a PLK1 inhibitor (IC50=2 nM) with high selectivity and oral activity. Onvansertib has antitumor activity and inhibits tumor growth.

PI3K-IN-31 (Compound 6b) is a potent PI3K inhibitor with IC50 values of 3.7 nM for PI3Kα, 74 nM for PI3Kβ, 14.6 nM for PI3Kγ, and 9.9 nM for PI3Kδ. PI3K-IN-31 has demonstrated anticancer activity.

SGC agonist 1 is a potent soluble guanylate cyclase (SGC) agonist that enhances solubility and exhibits high cell permeability.

BTK-IN-6 is a potent inhibitor of Bruton's tyrosine kinase (BTK) with research potential in immune diseases, cardiovascular diseases, cancer, viral infections, inflammation, metabolic/endocrine dysfunction, and neurological disorders (for more information).

Edecesertib (GS-5718) is a selective, orally active IRAK-4 inhibitor with anti-inflammatory properties, applicable for the study of rheumatoid arthritis (RA) and lupus erythematosus (LE).

JS1310 is a selective PRMT7 inhibitor (IC50: 5 μM against human PRMT7). JS1310 has shown anti-cancer effects on different cancer cells.

Chitin synthase inhibitor 7 (compound 9c), a potent inhibitor of chitin synthase (CHS) with an IC50 of 0.37 nM, can be used to study fungal infections.

Trimazosin is an orally active quinazoline derivative, structurally related to prazosin. trimazosin has hypotensive activity by selectively blocking alpha1-adrenoceptors.

Tubulin aggregation-IN-18 (compound 3) is a potent tubulin aggregation inhibitor with potential for breast cancer and drug-resistant colon cancer studies.

SOS1-IN-9 is a potent inhibitor of SOS1 that targets KRAS G12C-SOS1 with an IC50 of 116.5 nM.

3CPLro-IN-1 (compound A17) is a potent, orally active inhibitor of SARS-CoV-2 3-Chymotrypsin-like cysteine protease (3CLpro) with an IC50 of 5.65 μM, making it an attractive drug target against COVID-19 and also considered an antitumor agent-51.